115 assets in Hematopoietic And Lymphoid Cell Neoplasm

Therapeutic assets addressing Hematopoietic And Lymphoid Cell Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Rimiducid Hematopoietic And Lymphoid Cell Neoplasm	Bellicum Pharmaceuticals	P1	C (39)
Tagraxofusp Hematopoietic And Lymphoid Cell Neoplasm	Therapeutic Advances in Childhood Leukemia Consortium	P1	C (39)
Tgrx-1942 Hematopoietic And Lymphoid Cell Neoplasm	Shenzhen TargetRx Co., Ltd.	P1	C (39)
trx103 Hematopoietic And Lymphoid Cell Neoplasm	Tr1X, Inc.	P1	C (39)
Vactosertib Hematopoietic And Lymphoid Cell Neoplasm	David Wald	P1	C (39)
wbc100 qd Hematopoietic And Lymphoid Cell Neoplasm	Hangzhou Weben Pharma Co., Ltd	P1	C (39)
Ziftomenib Hematopoietic And Lymphoid Cell Neoplasm	Kura Oncology, Inc.	P1	C (39)
Daratumumab Hematopoietic And Lymphoid Cell Neoplasm	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Early P1	C (36)
Hyaluronidase Fihj Hematopoietic And Lymphoid Cell Neoplasm	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Early P1	C (36)
Apg-3288 Hematopoietic And Lymphoid Cell Neoplasm	Ascentage Pharma Group Inc.	P1	NR ()

Showing 101 to 115 of 115 assets

PreviousPage 3 of 3Next